IS4627A - Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid - Google Patents

Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid

Info

Publication number: IS4627A
Authority: IS; Iceland
Prior art keywords: monoglyceride; inhibitor; pharmaceutical composition; protein cleavage; cleavage catalyst
Prior art date: 1995-06-06

Application number

IS4627A

Other languages

English (en)

Other versions

IS2661B (is

Inventor

Ann Bailey Carole

Josephine Ferdinando Christine

Shah Navnit

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1997-12-04

Publication date

1997-12-04

1996-05-07 Priority claimed from US08/616,233 external-priority patent/US6008228A/en

1997-12-04 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

1997-12-04 Publication of IS4627A publication Critical patent/IS4627A/is

2010-08-15 Publication of IS2661B publication Critical patent/IS2661B/is

Links

LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 title 1
239000003054 catalyst Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000007026 protein scission Effects 0.000 title 1
239000000203 mixture Substances 0.000 abstract 2
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 abstract 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
150000004667 medium chain fatty acids Chemical class 0.000 abstract 1
239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Furan Compounds (AREA)
Pyrrole Compounds (AREA)
Quinoline Compounds (AREA)
Pyridine Compounds (AREA)
Pyrane Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)

IS4627A 1995-06-06 1997-12-04 Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid IS2661B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46849395A	1995-06-06	1995-06-06
US08/616,233 US6008228A (en)	1995-06-06	1996-05-07	Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en)	1995-06-06	1996-06-04	Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (2)

Publication Number	Publication Date
IS4627A true IS4627A (is)	1997-12-04
IS2661B IS2661B (is)	2010-08-15

Family

ID=27042422

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4627A IS2661B (is)	1995-06-06	1997-12-04	Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid

Country Status (26)

Country	Link
EP (1)	EP0831826B1 (is)
JP (1)	JP3238412B2 (is)
CN (1)	CN1092960C (is)
AT (1)	ATE226075T1 (is)
AU (1)	AU709796B2 (is)
BG (1)	BG63711B1 (is)
BR (1)	BR9610842A (is)
CA (1)	CA2224125C (is)
CY (1)	CY2373B1 (is)
CZ (1)	CZ292192B6 (is)
DE (1)	DE69624354T2 (is)
DK (1)	DK0831826T3 (is)
EA (1)	EA001413B1 (is)
ES (1)	ES2182996T3 (is)
HU (1)	HU223899B1 (is)
IL (1)	IL122353A0 (is)
IS (1)	IS2661B (is)
MX (1)	MX9709193A (is)
NO (1)	NO324531B1 (is)
NZ (1)	NZ311646A (is)
OA (1)	OA10546A (is)
PL (1)	PL184820B1 (is)
PT (1)	PT831826E (is)
SK (1)	SK282121B6 (is)
TR (1)	TR199701541T1 (is)
WO (1)	WO1996039142A1 (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4524367B2 (ja)	1997-07-29	2010-08-18	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	自己乳化性処方形態の酸性親油性化合物用の医薬組成物
DK0999838T3 (da) *	1997-07-29	2002-07-08	Upjohn Co	Selv-emulgerende formulering for lipofile forbindelser
EP1152749B1 (en) *	1999-02-08	2006-04-12	ALZA Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en)	1999-02-08	2007-08-21	Alza Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en)	1999-02-08	2011-04-05	Intarcia Therapeutics, Inc.	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6956048B2 (en)	1999-03-31	2005-10-18	Pharmacia & Upjohn Company	Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) *	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt)	2002-06-12	2004-06-29	Cristalia Prod Quimicos Farm	Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en)	2006-05-30	2010-09-22	Intarcia Therapeutics, Inc	Two-piece, internal-channel osmotic delivery system flow modulator
EP2157967B1 (en)	2007-04-23	2013-01-16	Intarcia Therapeutics, Inc	Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en)	2008-02-13	2012-06-06	Intarcia Therapeutics, Inc	Devices, formulations, and methods for delivery of multiple beneficial agents
EP2108705A1 (en)	2008-04-08	2009-10-14	Universität Duisburg-Essen	Method for analysing the epigenetic status of the HtrA 1 gene in a biological sample
EP3323423B1 (en)	2009-09-28	2020-06-17	Intarcia Therapeutics, Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
KR20240037175A (ko)	2016-05-16	2024-03-21	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
AU2018206539A1 (en)	2017-01-03	2019-07-18	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8927913D0 (en) *	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
IL110752A (en) *	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

1996
- 1996-06-04 ES ES96921929T patent/ES2182996T3/es not_active Expired - Lifetime
- 1996-06-04 JP JP50014397A patent/JP3238412B2/ja not_active Expired - Lifetime
- 1996-06-04 BR BR9610842A patent/BR9610842A/pt not_active IP Right Cessation
- 1996-06-04 PT PT96921929T patent/PT831826E/pt unknown
- 1996-06-04 EP EP96921929A patent/EP0831826B1/en not_active Expired - Lifetime
- 1996-06-04 EA EA199800023A patent/EA001413B1/ru not_active IP Right Cessation
- 1996-06-04 DK DK96921929T patent/DK0831826T3/da active
- 1996-06-04 AU AU63004/96A patent/AU709796B2/en not_active Expired
- 1996-06-04 CN CN96194327A patent/CN1092960C/zh not_active Expired - Lifetime
- 1996-06-04 SK SK1627-97A patent/SK282121B6/sk not_active IP Right Cessation
- 1996-06-04 IL IL12235396A patent/IL122353A0/xx not_active IP Right Cessation
- 1996-06-04 HU HU9801905A patent/HU223899B1/hu active IP Right Grant
- 1996-06-04 AT AT96921929T patent/ATE226075T1/de active
- 1996-06-04 DE DE69624354T patent/DE69624354T2/de not_active Expired - Lifetime
- 1996-06-04 NZ NZ311646A patent/NZ311646A/en not_active IP Right Cessation
- 1996-06-04 CZ CZ19973803A patent/CZ292192B6/cs not_active IP Right Cessation
- 1996-06-04 TR TR97/01541T patent/TR199701541T1/xx unknown
- 1996-06-04 PL PL96323860A patent/PL184820B1/pl unknown
- 1996-06-04 MX MX9709193A patent/MX9709193A/es unknown
- 1996-06-04 WO PCT/EP1996/002431 patent/WO1996039142A1/en not_active Ceased
- 1996-06-04 CA CA002224125A patent/CA2224125C/en not_active Expired - Lifetime
1997
- 1997-12-04 IS IS4627A patent/IS2661B/is unknown
- 1997-12-05 BG BG102106A patent/BG63711B1/bg unknown
- 1997-12-05 NO NO19975665A patent/NO324531B1/no not_active IP Right Cessation
- 1997-12-05 OA OA70151A patent/OA10546A/en unknown
2003
- 2003-08-22 CY CY0300057A patent/CY2373B1/xx unknown

Also Published As

Publication number	Publication date
ATE226075T1 (de)	2002-11-15
ES2182996T3 (es)	2003-03-16
HK1010136A1 (en)	1999-06-17
TR199701541T1 (xx)	1998-03-21
JPH10507202A (ja)	1998-07-14
EA199800023A1 (ru)	1998-08-27
CA2224125A1 (en)	1996-12-12
WO1996039142A1 (en)	1996-12-12
CN1092960C (zh)	2002-10-23
HUP9801905A2 (hu)	1999-05-28
NO975665D0 (no)	1997-12-05
AU709796B2 (en)	1999-09-09
BG102106A (en)	1998-08-31
PL323860A1 (en)	1998-04-27
JP3238412B2 (ja)	2001-12-17
CA2224125C (en)	2004-09-28
EP0831826A1 (en)	1998-04-01
BR9610842A (pt)	1999-07-13
NO975665L (no)	1998-02-05
SK162797A3 (en)	1998-05-06
AU6300496A (en)	1996-12-24
CZ380397A3 (cs)	1998-03-18
NO324531B1 (no)	2007-11-12
EP0831826B1 (en)	2002-10-16
IL122353A0 (en)	1998-04-05
OA10546A (en)	2002-05-29
CY2373B1 (en)	2004-06-04
DE69624354T2 (de)	2003-06-05
HU223899B1 (hu)	2005-03-29
BG63711B1 (bg)	2002-10-31
CZ292192B6 (cs)	2003-08-13
PL184820B1 (pl)	2002-12-31
NZ311646A (en)	2000-02-28
HUP9801905A3 (en)	2001-04-28
DK0831826T3 (da)	2003-02-03
CN1186434A (zh)	1998-07-01
DE69624354D1 (de)	2002-11-21
IS2661B (is)	2010-08-15
MX9709193A (es)	1998-03-31
EA001413B1 (ru)	2001-02-26
SK282121B6 (sk)	2001-11-06
PT831826E (pt)	2003-02-28

Publication	Publication Date	Title
BR9610842A (pt)	1999-07-13	Composição farmacêutica compreendendo um inibidor de proteinase e um monoglicerídeo
ZA9811830B (en)	2000-06-23	Prodrugs of aspartyl protease inhibitors.
TR200100432T2 (tr)	2001-09-21	Hepatit C inhibitörü tri-peptidler
FI973360L (fi)	1997-08-15	Uusia dipeptidisiä amidiineja trombiininestäjiksi
AU7473398A (en)	1998-11-27	Inhibitors of protein isoprenyl transferases
LV11951A (lv)	1998-01-20	Mikrosomalo trigliceridu transportproteinu inhibitors
NO981938D0 (no)	1998-04-29	Proteaseinhibitorer
NO982809L (no)	1998-08-20	Prolegemidler av tombin-inhibitorer
DK1341533T3 (da)	2006-05-08	Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme
ATE218336T1 (de)	2002-06-15	Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
AU7117496A (en)	1997-04-28	Peptide inhibitor for viral protease derived from the transframe region of the gag-pol gene
MY116525A (en)	2004-02-28	Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
SE9601556D0 (sv)	1996-04-24	New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DK0842185T3 (da)	2002-02-04	Ara-C-derivater
NO20004664L (no)	2000-09-19	FremgangsmÕte for fremstilling av HIV proteaseinhibitorer
AU6678398A (en)	1998-09-18	Inhibitors of isoprenyl transferase
EP1030661A4 (en)	2002-07-17	N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
AU8297698A (en)	1999-02-08	Inhibitors of neutrophil mediated oxidant production
HK1032225A (en)	2001-07-13	Prodrugs of aspartyl protease inhibitors
ECSP961778A (es)	1997-11-04	Composiciones que incrementan la biodisponibilidad de inhibidores de proteinasa